Recursion CEO Chris Gibson defends the NIH, investing $1 million into a pre-seed venture to encourage critical research and innovation in the biotech space.
By registering you consent to the collection and use of your information to provide the products and services you have requested from us and as described in our privacy policy and terms and conditions ...
For now, U.S. public health officials face ebbing public trust as well as a disruptive new health administration led by skeptics of established medicine.
In January, standing before a cluster of television cameras on the steps of the state Capitol, Georgia Gov. Brian Kemp promoted his experiment in Medicaid reform as a showcase for fellow conservatives ...
So far, Pathways has cost state and federal taxpayers nearly $9,000 per enrollee, largely back-end costs to run the program. States that have expanded Medicaid spent about $6,500 per enrollee in that ...
In a true David vs. Goliath battle, nimble independent agencies are defying the "bigger is better" narrative, winning top clients and industry awards with smart investments, speed, and agility.
Many of the state’s medical providers are behind the effort, saying prior authorization is denying vital care and needlessly sucking up more and more of their time.
New treatments can slow the disease’s progress, which is why the Alzheimer’s Association is leveraging its celebrity partners ...
The 21 members of the Class of 2025 will be honored at a gala celebration on May 7 at New York City’s Edison Ballroom.
The amounts represent what Medicaid spent covering the residents’ care when they lived at the Glenwood Resource Center, a state-run facility that closed last summer.
As many doctors were scaling back their use of prescription painkillers due to the opioid crisis, Pain MD paired opioids with monthly injections into patients’ backs.
The New Jersey-based drugmaker secured a conditional license to protect chickens with its H5N2 subtype vaccine.